Multicenter evaluation of the antimicrobial activity for six broad-spectrum β-lactams in Venezuela: Comparison of data from 1997 and 1998 using the Etest method

Diagnostic Microbiology and Infectious Disease

Volumn 35, Issue 2, 1999, Pages 153-158

  Pfaller, Michael A ^a   Jones, Ronald N ^a   Doern, Gary V ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; IMIPENEM; OXACILLIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CITROBACTER FREUNDII; CONTROLLED STUDY; DRUG SENSITIVITY; ENTEROBACTER; ENTEROBACTERIACEAE; HOSPITAL LABORATORY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; SERRATIA; STAPHYLOCOCCUS AUREUS; VENEZUELA;

ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAMS; CEPHALOSPORINASE; DRUG RESISTANCE, MICROBIAL; ENTEROBACTERIACEAE; STAPHYLOCOCCUS; TIME FACTORS; VENEZUELA;

EID: 0032747156     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00071-1     Document Type: Article

References (30)

1. Archibald L., Phillips L., Monnet D., McGowan J.E. Jr, Tenover F., Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States increasing importance of the intensive care unit . Clin Infect Dis. 24:1997;211-215.
2. Report of the ASM Task Force on Antibiotic Resistance. Antimicrob Agents Chemother. 6:(suppl):1995;1-23.
3. Blondeau J.M., Yaschuk Y. Canadian multicenter susceptibility study, with a focus on cephalosporins, from 15 Canadian medical centers. Antimicrob Agents Chemother. 41:1997;2773-2775.
4. Brown D.F.J., Brown L. Evaluation of the Etest a novel method of quantifying antimicrobial activity . J Antimicrob Chemother. 27:1991;185-190.
5. Colombian Antimicrobial Resistance Study Group, Jones RN, Salazar JC, Pfaller MA, Doern GV, Lozano F (1997) Multicenter evaluation of the antimicrobial activity for six broad-spectrum β-lactams in Colombia using the Etest method. Diagn Microbiol Infect Dis 29:265-272.
6. Coronado V., Gaynes R.P., Edwards J. The national nosocomial infection surveillance system. Ciprofloxacin resistance among Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol. 15:1994;23.
7. Felmingham D., Gruneberg R.N. A multicenter collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993 the Alexander Project . J Antimicrob Chemother. 38:(suppl A):1996;1-57.
8. Gaynes R. The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals. Infect Dis Clin N Am. 11:1997;757-765.
9. Gold S.G., Moellering R.C. Antimicrobial drug resistance. N Engl J Med. 335:1996;1445-1453.
10. Jacoby G.A., Carreras I. Activities of β-lactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases. Antimicrob Agents Chemother. 34:1990;858-862.
11. Jones R.N. The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Diagn Microbiol Infect Dis. 25:1996;1-9.
12. Jones R.N., Marshall S.A. Antimicrobial activity of cefepime tested against Bush group 1 β-lactamase-producing strains resistant to ceftazidime. Diagn Microbiol Infect Dis. 19:1994;33-38.
13. Jones R.N., Kehrberg E.N., Erwin M.E., Anderson S.C. The prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States study on the threat of emerging resistance, real or perceived? Diagn Microbiol Infect Dis. 19:1994;203-215.
14. Jones R.N., Baquero F., Privitera G., Inoue M., Wiedemann B. Inducible β-lactamase-mediated resistance to third-generation cephalosporins. Clin Microbiol Infect. 3:(suppl 1):1997;S7-S20.
15. Jones R.N., Pfaller M.A., Doern G.V., Erwin M.E., Hollis R.J. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs a 1997 surveillance trial in 102 medical centers in the United States . Diagn Microbiol Infect Dis. 30:1998;215-228.
16. Jones M.E. Towards better surveillance of bacterial antibiotic resistance. Clin Microbiol Infect. 5:1999;61-63.
17. National Committee for Clinical Laboratory Standards (1997) Performance standards for antimicrobial disk susceptibility tests: Approved standard M2-A6. Wayne, PA: NCCLS.
18. National Committee for Clinical Laboratory Standards (1999) Performance standards for antimicrobial susceptibility testing. 9th informational supplement M100-S9. Wayne, PA: NCCLS.
19. Neu H.C. The crisis in antibiotic resistance. Science. 257:1992;1064-1073.
20. Philippon A., Arlet G., Lagrange P.H. Origin and impact of plasmid-mediated extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 13:1994;17-29.
21. Pfaller M.A., Jones R.N., Marshall S.A., Coffman S.L., Hollis R.J., Edmond M.B., Wenzel R.P. Inducible Amp C β-lactamase producing gram-negative bacilli from blood stream infections frequency, antimicrobial susceptibility, and molecular epidemiology in a National Surveillance Program (SCOPE) . Diagn Microbiol Infect Dis. 28:1997;211-219.
22. Pfaller M.A., Jones R.N., Doern G.V., Kugler K. Bacterial pathogens isolated from patients with blood stream infections frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997) . Antimicrob Agents Chemother. 42:1998;1762-1770.
23. Pfaller M.A., Jones R.N., Doern G.V., Sader H.S., Kugler K.C., Beach M.L. Survey of blood stream infections due to Gram-positive cocci frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program . Diagn Microbiol Infect Dis. 33:1999;283-297.
24. Puerto Rico Antimicrobial Resistance Study Group, Doern GV, Jones RN, Pfaller MA, Erwin ME, Ramirez-Rhonda C (1998) Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. Diagn Microbiol Infect Dis 30:113-119.
25. Sader H.S., Mimica I., Rossi F., Zoccoli C., Montelli A.C., Sampaio J.L.M., Segura A.J.A., Magalhees M., Nowakonski A., Mendes C.M.F. Evaluation of the in vitro activity of cefepime compared to other broad-spectrum cephalosporins against clinical isolates from eighteen Brazilian hospitals by using the Etest. Diagn Microbiol Infect Dis. 28:1997;87-92.
26. Sahm DF, Hickey ML, Marsilio MK, Heller BH, Tomfohrde KM, Thornsberry C (1998) Detection and prevalence of extended spectrum β-lactamase (ESBL) producing strains by applying National Committee for Clinical Laboratory Standards (NCCLS) guidelines to The Surveillance Network (TSN) Database-USA (Abstr. C32). 98th General Meeting of the American Society for Microbiology, Atlanta, GA, 1998. Washington, DC: American Society for Microbiology.
27. Spencer R.C., Bauernfeind A., Garcia-Rodriguez J., Jarlier V., Pfaller M., Turnidge J., Voss A. Surveillance of the current resistance of nosocomial pathogens to antibacterials. Clin Microbiol Infect Dis. 3:(suppl 1):1997;S21-S35.
28. Stephenson J. Worry grows as antibiotic-resistant bacteria continue to gain ground. JAMA. 278:1997;2049-2050.
29. Venezuelan Antimicrobial Resistance Study Group, Pfaller MA, Jones RN, Doern GV (1998) Multicenter evaluation of the antimicrobial activity for six broad-spectrum β-lactams in Venezuela using the Etest method. Diagn Microbiol Infect Dis 30:45-52.
30. Williams R.J., Heymann D.L. Containment of antibiotic resistance. Science. 279:1998;1153-1154.